Filing Details

Accession Number:
0001209191-21-060235
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-10-12 16:33:23
Reporting Period:
2021-10-07
Accepted Time:
2021-10-12 16:33:23
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1808865 Iteos Therapeutics Inc. ITOS () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1134655 Ansbert Gadicke C/O Mpm Capital
450 Kendall Street
Cambridge MA 02142
No No Yes No
1687078 Bioimpact Capital Llc C/O Mpm Capital
450 Kendall Street
Cambridge MA 02142
No No Yes No
1691428 L.p. Fund Impact Oncology Ubs C/O Mpm Capital
450 Kendall Street
Cambridge MA 02142
No No Yes No
1721036 L.p. Management (Cayman) Fund Impact Oncology C/O Mpm Capital
450 Kendall Street
Cambridge MA 02142
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-10-07 1,922 $27.00 5,345,915 No 4 S Indirect See Footnote
Common Stock Disposition 2021-10-08 3,400 $27.01 5,342,515 No 4 S Indirect See Footnote
Common Stock Disposition 2021-10-11 81,684 $27.24 5,260,831 No 4 S Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
Footnotes
  1. Transaction effected pursuant to a plan established pursuant to Rule 10b5-1.
  2. The shares were sold as follows: 684 by MPM BioVentures 2014, L.P. ("BV 2014"), 24 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 432 by MPM BioVentures 2018, L.P. ("BV 2018"), 9 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 773 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC.
  3. BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. The shares are held as follows: 1,845,606 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 63,523 by AM BV2014, 1,165,645 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 23,004 by AM BV2018 and 2,086,211 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
  6. The shares were sold as follows: 1,210 by BV 2014, 42 by AM BV2014, 765 by BV 2018, 15 by AM BV2018 and 1,368 by UBS Oncology.
  7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.97 to $27.035 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  8. The shares are held as follows: 1,844,396 by BV 2014, 107,713 by BV 2014(B), 63,481 by AM BV2014, 1,164,880 by BV 2018, 54,213 by BV 2018(B), 22,989 by AM BV2018 and 2,084,843 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
  9. The shares were sold as follows: 29,081 by BV 2014, 1,001 by AM BV2014, 18,367 by BV 2018, 363 by AM BV2018 and 32,872 by UBS Oncology.
  10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.53 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  11. The shares are held as follows: 1,815,315 by BV 2014, 107,713 by BV 2014(B), 62,480 by AM BV2014, 1,146,513 by BV 2018, 54,213 by BV 2018(B), 22,626 by AM BV2018 and 2,051,971 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.